The FDA's all-oral acute myeloid leukemia regimen carries forward into Saturday with the same boundary it landed with on Wednesday. Friday's paper described how oral decitabine and cedazuridine with venetoclax moves part of cancer care to the kitchen table, and the convenience win remains real. The label, however, has not widened in 72 hours.

The approval is for newly diagnosed AML in adults at least 75 years old, or younger adults who are ineligible for intensive induction chemotherapy because of comorbidities. [1] That is the registrational population, and Taiho's release uses the same eligibility clause. [2] An oncologist deciding whether to switch a 62-year-old fit patient onto the oral combination today is making an off-label call, not a label call.

The discipline matters because the social-media frame keeps drifting toward "oral AML treatment now exists." It exists for the trial population. The infusion chair stays in the picture for everyone else, including patients whose cytogenetics and performance status put them inside induction protocols.

Adherence is the other clause the headline keeps losing. Oral combinations only deliver their convenience benefit when the monitoring plan follows the pills home: lab visits, infection thresholds, missed-dose protocols, caregiver checks. The label gives the regimen; the clinic still has to give the wraparound.

A first all-oral combination is a real first. It is not yet a standard of care for AML. The next eligibility expansion will need its own trial, its own readout, and its own label line.

-- NORA WHITFIELD, Chicago